Abvc Biopharma (ABVC) Other financing activities (2023 - 2026)
Abvc Biopharma's (ABVC) quarterly Other financing activities came in at $319492.0 in Q1 2026, down 22.39% YoY from $411667.0 in Q1 2025, and up 117.89% on a QoQ basis from -$1.8 million in Q4 2025.
Abvc Biopharma (ABVC) Other financing activities (2023 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 4 years of Other financing activities data on file, last reported at $319492.0 in Q1 2026.
- Quarterly Other financing activities fell 22.39% year-over-year to $319492.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $899191.0 (up 118.43% YoY) and the FY2025 annual result came in at $991366.0, up 151.57% from the prior year.
- Other financing activities advanced to $319492.0 in Q1 2026, from -$1.8 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $2.4 million in Q3 2025 to a low of -$1.8 million in Q4 2025.
- A 4-year average of $210279.9 and a median of $291261.5 in 2024 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2025 — Other financing activities surged 799.31% — and 2026, when it fell 22.39%.
- Tracing ABVC's Other financing activities over 4 years: stood at -$22690.0 in 2023, then surged by 1259.24% to $263031.0 in 2024, then sank by 778.91% to -$1.8 million in 2025, then soared by 117.89% to $319492.0 in 2026.
- The last three Other financing activities figures came in at $319492.0 (Q1 2026), -$1.8 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -217,492.00 |
| Jun 30, 2026 | -217,492.00 |
| Mar 31, 2026 | 319,492.00 |
| Mar 31, 2026 | 319,492.00 |
| Dec 31, 2025 | -1.79 Mn |
| Dec 31, 2025 | -1.79 Mn |
| Sep 30, 2025 | 2.37 Mn |
| Sep 30, 2025 | 2.37 Mn |
| Mar 31, 2025 | 411,667.00 |
| Mar 31, 2025 | 411,667.00 |
| Sep 30, 2024 | 263,031.00 |
| Sep 30, 2024 | 263,031.00 |
| Jun 30, 2024 | -263,031.00 |
| Jun 30, 2024 | -263,031.00 |
| Mar 31, 2024 | 394,071.00 |
| Mar 31, 2024 | 394,071.00 |
| Dec 31, 2023 | -22,690.00 |
| Dec 31, 2023 | -22,690.00 |